The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Proteases and protease inhibitors in infectious diseases
Abstract
There are numerous proteases of pathogenic organisms that are currently targeted for therapeutic intervention along with many that are seen as potential drug targets. This review discusses the chemical and biological makeup of some key druggable proteases expressed by the five major classes of disease causing agents, namely bacteria, viruses, fungi, eukaryotes, and prions. While a few of these enzymes including HIV protease and HCV NS3‐4A protease have been targeted to a clinically useful level, a number are yet to yield any clinical outcomes in terms of antimicrobial therapy. A significant aspect of this review discusses the chemical and pharmacological characteristics of inhibitors of the various proteases discussed. A total of 25 inhibitors have been considered potent and safe enough to be trialed in humans and are at different levels of clinical application. We assess the mechanism of action and clinical performance of the protease inhibitors against infectious agents with their developmental strategies and look to the next frontiers in the use of protease inhibitors as anti‐infective agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Candida albicans Secreted Aspartyl Proteinases in Virulence and Pathogenesis
Naglik, J. R., Challacombe, S. J., & Hube, B. (2003) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.67.3.400-428.2003 · Cited by 1,179
Wolfsberg, T. G., Primakoff, P., Myles, D. G., & White, J. M. (1995) · The Journal of cell biology · doi:10.1083/jcb.131.2.275 · Cited by 502
Hoy, B., Löwer, M., Weydig, C., Carra, G., Tegtmeyer, N., Geppert, T., Schröder, P., Sewald, N., Backert, S., Schneider, G., et al. (2010) · The EMBO Reports · doi:10.1038/embor.2010.114 · Cited by 295
Böttcher, T., & Sieber, S. A. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8051365 · Cited by 207
Bacterial Proteases and Virulence
Frees, D., Brøndsted, L., & Ingmer, H. (2013) · Subcellular Biochemistry · doi:10.1007/978-94-007-5940-4_7 · Cited by 159
Cited by
The SARS-CoV-2 main protease as drug target
Ullrich, S., & Nitsche, C. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127377 · Cited by 772
Unoh, Y., Uehara, S., Nakahara, K., Nobori, H., Yamatsu, Y., Yamamoto, S., Maruyama, Y., Taoda, Y., Kasamatsu, K., Suto, T., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00117 · Cited by 598
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
Fu, L., Ye, F., Feng, Y., Yu, F., Wang, Q., Wu, Y., Zhao, C., Sun, H., Huang, B., Niu, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18233-x · Cited by 529
Freitas, B. T., Durie, I. A., Murray, J., Longo, J. E., Miller, H. C., Crich, D., Hogan, R. J., Tripp, R. A., & Pegan, S. D. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00168 · Cited by 290
Metadata
- Authors
- Agbowuro, A. A., Huston, W. M., Gamble, A. B., & Tyndall, J. D. A.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2017-11-17
- Volume
- 38
- Issue
- 4
- Pages
- 1295-1331
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2768652310
- Cited by
- 186
- References
- 5
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteases and protease inhibitors in infectious diseases. https://app.cochat.ai/papers/10.1002/med.21475
- The paper
- Agbowuro, A. A., Huston, W. M., Gamble, A. B., & Tyndall, J. D. A. (2018). Proteases and protease inhibitors in infectious diseases. Medicinal Research Reviews. https://doi.org/10.1002/med.21475
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.